MiR-206 Regulates Cisplatin Resistance and EMT in Human Lung Adenocarcinoma Cells Partly by Targeting MET

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Mar 26

PMID 27014910

Citations 55

Authors

Qing-Yong Chen

De-Min Jiao

Jian Wang

Huizhen Hu

Xiali Tang

Jun Chen

Hao Mou

Wei Lu

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) play a critical role in drug resistance and epithelial-mesenchymal transition (EMT). The aims of this study were to explore the potential role of miR-206 in governing cisplatin resistance and EMT in lung cancer cells. We found that both lung adenocarcinoma A549 cisplatin-resistant cells (A549/DDP) and H1299 cisplatin-resistant cells (H1299/DDP) acquired mesenchymal features and were along with low expression of miR-206 and high migration and invasion abilities. Ectopic expression of miR-206 mimics inhibited cisplatin resistance, reversed the EMT phenotype, decreased the migration and invasion in these DDP-resistant cells. In contrast, miR-206 inhibitors increased cisplatin resistance, EMT, cell migration and invasion in non-DDP-resistant cells. Furthermore, we found that MET is the direct target of miR-206 in lung cancer cells. Knockdown of MET exhibited an EMT and DDP resistant inhibitory effect on DDP-resistant cells. Conversely, overexpression of MET in non-DDP- resistant cells produced a promoting effect on cell EMT and DDP resistance. In lung adenocarcinoma tissues, we demonstrated that low expression of miR-206 were also correlated with increased cisplatin resistance and MET expression. In addition, we revealed that miR-206 overexpression reduced cisplatin resistance and EMT in DDP-resistant cells, partly due to inactivation of MET/PI3K/AKT/mTOR signaling pathway, and subsequent downregulation of MDR1, ZEB1 and Snail expression. Finally, we found that miR-206 could also sensitize A549/DDP cells to cisplatin in mice model. Taken together, our study implied that activation of miR-206 or inactivation of its target gene pathway could serve as a novel approach to reverse cisplatin resistance in lung adenocarcinomas cells.

Citing Articles

Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells.

Maharati A, Rajabloo Y, Moghbeli M Heliyon. 2025; 11(1):e41483.

PMID: 39834411 PMC: 11743095. DOI: 10.1016/j.heliyon.2024.e41483.

PI3K/AKT pathway as a pivotal regulator of epithelial-mesenchymal transition in lung tumor cells.

Moghbeli M Cancer Cell Int. 2024; 24(1):165.

PMID: 38730433 PMC: 11084110. DOI: 10.1186/s12935-024-03357-7.

TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT.

Chen X, Zhou Z, Tang P, Du F, Wang S, Yao J Curr Cancer Drug Targets. 2024; 25(1):72-82.

PMID: 38415469 PMC: 11826914. DOI: 10.2174/0115680096281231240202073558.

Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.

Sadeghi M, Lotfi M, Soltani N, Farmani E, Fernandez J, Akhlaghitehrani S Cancer Cell Int. 2023; 23(1):284.

PMID: 37986065 PMC: 10661689. DOI: 10.1186/s12935-023-03133-z.

Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts.

Khan N, Asim M, Biswas K, Alansari A, Saman H, Sarwar M J Exp Clin Cancer Res. 2023; 42(1):221.

PMID: 37641132 PMC: 10463467. DOI: 10.1186/s13046-023-02753-7.

References

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

Fischer K, Durrans A, Lee S, Sheng J, Li F, Wong S . Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579):472-6. PMC: 4662610. DOI: 10.1038/nature15748. View

Fumarola C, Bonelli M, Petronini P, Alfieri R . Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014; 90(3):197-207. DOI: 10.1016/j.bcp.2014.05.011. View

Liu H, Cao Y, Ye W, Sun Y . Effect of microRNA-206 on cytoskeleton remodelling by downregulating Cdc42 in MDA-MB-231 cells. Tumori. 2011; 96(5):751-5. DOI: 10.1177/030089161009600518. View

Li J, Wang Y, Song Y, Fu Z, Yu W . miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 2014; 13:193. PMC: 4158130. DOI: 10.1186/1476-4598-13-193. View

Wang K, Zhuang Y, Liu C, Li Y . Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch Biochem Biophys. 2012; 526(1):38-43. DOI: 10.1016/j.abb.2012.07.003. View

Miow Q, Tan T, Ye J, Lau J, Yokomizo T, Thiery J . Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 2014; 34(15):1899-907. DOI: 10.1038/onc.2014.136. View

Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y . Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget. 2015; 6(28):25533-74. PMC: 4694850. DOI: 10.18632/oncotarget.4575. View

Yang Q, Zhang C, Huang B, Li H, Zhang R, Huang Y . Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer. Eur J Gastroenterol Hepatol. 2013; 25(8):953-7. DOI: 10.1097/MEG.0b013e32835ed691. View

10.

Fujiwara M, Izuishi K, Sano T, Hossain M, Kimura S, Masaki T . Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res. 2008; 27:76. PMC: 2607265. DOI: 10.1186/1756-9966-27-76. View

11.

Zhao J, Chu Z, Hu Y, Lin J, Wang Z, Jiang M . Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015; 75(20):4384-4397. PMC: 4609291. DOI: 10.1158/0008-5472.CAN-15-0457. View

12.

Gao B, Yang F, Yu Z, Li R, Xie F, Chen J . Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors. Int J Clin Exp Pathol. 2015; 8(6):6995-7001. PMC: 4525923. View

13.

Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X . miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res. 2013; 19(4):677-83. DOI: 10.1007/s12253-013-9630-4. View

14.

Tania M, Khan M, Fu J . Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014; 35(8):7335-42. DOI: 10.1007/s13277-014-2163-y. View

15.

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A . Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007; 31(2):277-83. View

16.

Bian H, Pan X, Yang J, Wang Z, De W . Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011; 30:20. PMC: 3051912. DOI: 10.1186/1756-9966-30-20. View

17.

Ren J, Huang H, Gong Y, Yue S, Tang L, Cheng S . MicroRNA-206 suppresses gastric cancer cell growth and metastasis. Cell Biosci. 2014; 4:26. PMC: 4030529. DOI: 10.1186/2045-3701-4-26. View

18.

Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng X . miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer. 2012; 77(3):488-94. DOI: 10.1016/j.lungcan.2012.05.107. View

19.

Tan J, You Y, Xu T, Yu P, Wu D, Deng H . Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicol Lett. 2013; 224(1):7-15. DOI: 10.1016/j.toxlet.2013.10.008. View

20.

Tan X, Moyer A, Fridley B, Schaid D, Niu N, Batzler A . Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2011; 17(17):5801-11. PMC: 3167019. DOI: 10.1158/1078-0432.CCR-11-1133. View